Faculty Profiles - MAEDA Yoshinobu

MISC - MAEDA Yoshinobu

Division display 21 - 40 of about 319 ／ All the affair displays >>

Marfan症候群に先天性第XI因子欠乏症とvon Willebrand病(VWD)を合併した患者の心臓弁膜症手術の周術期管理

大山矩史, 淺田騰, 末澤孝徳, 新谷憲治, 廣田真規, 池内一廣, 北村亘, 高須賀裕樹, 藤原英晃, 遠西大輔, 西森久和, 藤井伸治, 松岡賢市, 笠原真悟, 前田嘉信

臨床血液 62 ( 6 ) 663 - 663 2021

Treatment outcome of relapse/refractory DLBCL by tisagenlecleucel

北村亘, 淺田騰, 藤原英晃, 藤井伸治, 池内一廣, 高須賀裕樹, 大山矩史, 小林宏紀, 福見拓也, 佐伯恭昌, 廻勇輔, 遠西大輔, 西森久和, 藤井敬子, 松岡賢市, 松村卓郎, 今村豊, 前田嘉信

日本造血細胞移植学会総会プログラム・抄録集 43rd 2021

造血幹細胞移植後の粘膜障害による下痢および肛門痛に対するオキシコドン持続静注の効果

佐田光, 鍛治園誠, 佐藤晶子, 北村佳久, 片山英樹, 松岡順治, 西森久和, 前田嘉信, 千堂年昭

日本緩和医療薬学会年会プログラム・要旨集 14th 2021

A case of an 18-year-old man who was diagnosed with subcutaneous panniculitis-like T-cell lymphoma Reviewed

和田嵩平, 和田嵩平, 和田嵩平, 勝山隆行, 縄稚翔一, 吉田遥, 松本佳則, 三宅智子, 野村隼人, 中井友美, 山崎江利子, 西森久和, 大山矩史, 谷口恒平, 吉野正, 前田嘉信, 森実真, 和田淳

日本プライマリ・ケア連合学会学術大会(Web) 12th np444 - np444 2021

Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation (vol 60, pg 473, 2020)

Keisuke Seike, Nobuharu Fujii, Naomi Asano, Shigenori Ohkuma, Yasushi Hirata, Keiko Fujii, Yasuhisa Sando, Makoto Nakamura, Kazunori Naito, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-ichi Matsuoka, Kazuo Tsubaki, Fumio Otsuka, Yoshinobu Maeda

TRANSFUSION 60 ( 11 ) 2765 - 2765 2020.11

III期非小細胞肺癌に対する化学放射線療法後の放射線肺臓炎の検討

勝井邦彰, 尾形毅, 吉尾浩太郎, 黒田昌宏, 平木隆夫, 木浦勝行, 前田嘉信, 豊岡伸一, 金澤右

肺癌 60 ( 6 ) 577 - 577 2020.10

免疫チェックポイント阻害薬が有効なEGFR遺伝子変異陽性肺癌の特徴

市原英基, 原田大二郎, 井上考司, 柴山卓夫, 細川忍, 岸野大蔵, 張田信吾, 越智宣昭, 小田尚廣, 原尚史, 堀田勝幸, 前田嘉信, 木浦勝行

肺癌 60 ( 6 ) 637 - 637 2020.10

当院においてベンラリズマブを使用した重症気管支喘息症例の検討

谷口暁彦, 板野純子, 妹尾賢, 金廣有彦, 木浦勝行, 前田嘉信, 宮原信明

アレルギー 69 ( 臨時増刊号 ) 309 - 309 2020.10

マウス好中球性喘息モデルにおけるIL-23の役割の検討

妹尾賢, 谷口暁彦, 板野純子, 小田尚廣, 郭麗莉, 吉村昭彦, 木浦勝行, 前田嘉信, 宮原信明

日本呼吸器学会誌 9 ( 増刊 ) 227 - 227 2020.8

Successful re-administration of osimertinib in osimertinib-induced interstitial lung disease with an organizing pneumonia pattern: A case report and literature review

Junko Itano, Hisao Higo, Kadoaki Ohashi, Go Makimoto, Kazuya Nishii, Katsuyuki Hotta, Nobuaki Miyahara, Yoshinobu Maeda, Katsuyuki Kiura

Internal Medicine 59 ( 6 ) 823 - 828 2020.3

Language：English Publishing type：Book review, literature introduction, etc. Publisher：Japanese Society of Internal Medicine

Osimertinib is the standard therapy for epidermal-growth-factor-receptor (EGFR)-mutant lung cancers. We herein report a case of osimertinib-induced interstitial lung disease (OsiILD) with an organizing pneumonia (OP) pattern and provide a literature-based review. Six months after osimertinib administration, a 75-year-old woman with right pleural carcinomatosis developed ILD with an OP pattern. After salvage chemotherapy, osimertinib with corticosteroid was successfully re-administered. A literature review suggested that 1) OsiILD with an OP pattern was rare but should be recognized, and 2) re-administration of osimertinib in OsiILD was successful in select patients. A criterion that determines whether a patient would benefit from re-administration is warranted.

DOI： 10.2169/internalmedicine.3772-19

Scopus

PubMed

researchmap

The effect of protein sufficiency during early hematopoietic stem cell transplantation on hospital stay and transplantation-related mucosal disorder

庄野三友紀, 長谷川祐子, 佐田光, 杉浦裕子, 海内千春, 高橋郁名代, 岩谷美貴子, 四方賢一, 中川美緒, 佐藤あやめ, 曽我賢彦, 西森久和, 藤井伸治, 前田嘉信

日本造血細胞移植学会総会プログラム・抄録集 42nd 2020

Gonadal function of female patients after stem cell transplantation

岡本幸代, 岡本幸代, 藤井伸治, 佐伯恭昌, 久保寿夫, 西森久和, 松岡賢市, 前田嘉信

日本造血細胞移植学会総会プログラム・抄録集 42nd 2020

Efficacy of Oral cryotherapy on Oral Mucositis in Patients Received Hematopoietic Stem Cell Transplantation with Melphalan

中川美緒, 室美里, 佐藤あやめ, 佐藤あやめ, 岸本智子, 杉浦裕子, 海内千春, 佐田光, 西森久和, 前田嘉信, 曽我賢彦

日本造血細胞移植学会総会プログラム・抄録集 42nd 2020

PTCyは,移植前ニボルマブ治療を受けた患者のTreg恒常性を回復させ,急性GVHDを抑制する

池川俊太郎, 松岡賢市, 水原健太郎, 福見拓也, 小林宏紀, 住居優一, 近藤匠, 廻勇輔, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井伸治, 藤澤佑香, 今井利, 前田嘉信

日本血液学会学術集会抄録(Web) 82nd 2020

チサゲンレクルユーセル投与後の遷延性血球減少の2症例

福見拓也, 藤井伸治, 藤井伸治, 神原由依, 池内一廣, 小林宏紀, 木村真衣子, 木村真衣子, 近藤匠, 近藤匠, 松田真幸, 松田真幸, 池川俊太郎, 池川俊太郎, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井敬子, 松岡賢市, 前田嘉信

日本血液学会学術集会抄録(Web) 82nd 2020

B-ALL performed HLA haploidentical stem cell transplantation using post-transplant cyclophosphamide after administration of inotuzumab ozogemicin

阿部将也, 藤井伸治, 藤井伸治, 水原健太郎, 浦田知宏, 住居優一, 藤原悠紀, 清家圭介, 三道康永, 中村真, 藤井敬子, 佐伯恭昌, 廻勇輔, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 前田嘉信

日本造血細胞移植学会総会プログラム・抄録集 42nd 2020

NSCLCに対する免疫チェックポイント阻害薬の効果予測のためのTBNAまたはセルブロック検体を用いたPD-L1測定

原尚史, 市原英基, 原田大二郎, 井上考司, 藤原慶一, 細川忍, 岸野大蔵, 川井治之, 越智宣昭, 小田尚廣, 堀田勝幸, 前田嘉信, 木浦勝行

肺癌 59 ( 6 ) 775 - 775 2019.11

進行NSCLCにおけるTBNAまたはセルブロック検体でのPD-L1測定によるICIの効果予測

57回 P88 - 1 2019.10

Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. Reviewed International journal

Makimoto G, Ohashi K, Tomida S, Nishii K, Matsubara T, Kayatani H, Higo H, Ninomiya K, Sato A, Watanabe H, Kano H, Ninomiya T, Kubo T, Rai K, Ichihara E, Hotta K, Tabata M, Toyooka S, Takata M, Maeda Y, Kiura K

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 14 ( 11 ) 2009 - 2018 2019.7

Language：English

INTRODUCTION: The highly selective ALK receptor tyrosine kinase (ALK) inhibitor alectinib is standard therapy for ALK-positive lung cancers; however, some tumors quickly develop resistance. Here, we investigated the mechanism associated with rapid acquisition of resistance using clinical samples. METHODS: Autopsied samples were obtained from lung, liver, and renal tumors from a 51-year-old male patient with advanced ALK-positive lung cancer who had acquired resistance to alectinib in only 3 months. We established an alectinib-resistant cell line (ABC-14) from pleural effusion and an alectinib/crizotinib-resistant cell line (ABC-17) and patient-derived xenograft (PDX) model from liver tumors. Additionally, we performed next-generation sequencing, direct DNA sequencing, and quantitative real-time reverse transcription polymerase chain reaction. RESULTS: ABC-14 cells harbored no ALK mutations and were sensitive to crizotinib while also exhibiting MNNG HOS transforming gene (MET) gene amplification and amphiregulin overexpression. Additionally, combined treatment with crizotinib/erlotinib inhibited cell growth. ABC-17 and PDX tumors harbored ALK G1202R, and PDX tumors metastasized to multiple organs in vivo, whereas the third-generation ALK-inhibitor, lorlatinib, diminished tumor growth in vitro and in vivo. Next-generation sequencing indicated high tumor mutation burden and heterogeneous tumor evolution. The autopsied lung tumors harbored ALK G1202R (c. 3604 G>A) and the right renal metastasis harbored ALK G1202R (c. 3604 G>C); the mutation thus comprised different codon changes. CONCLUSIONS: High tumor mutation burden and heterogeneous tumor evolution might be responsible for rapid acquisition of alectinib resistance. Timely lorlatinib administration or combined therapy with an ALK inhibitor and other receptor tyrosine-kinase inhibitors might constitute a potent strategy.

DOI： 10.1016/j.jtho.2019.07.017

PubMed

researchmap

Significant combination benefit of anti-VEGFR antibody and oncogene-targeted agents in EGFR or ALK mutant NSCLC cells

Hiromi Watanabe, Eiki Ichihara, Hiroe Kayatani, Hisao Higo, Go Makimoto, Hirohisa Kano, Kazuya Nishii, Naofumi Hara, Kiichiro Ninomiya, Toshio Kubo, Kadoaki Ohashi, Kammei Rai, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

CANCER RESEARCH 79 ( 13 ) 2019.7

　 PREV - NEXT 　

< MAEDA Yoshinobu >

MISC - MAEDA Yoshinobu